Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

Phase 2 Unknown 32 enrolled University of Kansas Medical Center Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

Primary Study Objective: To assess the pathological complete response rate (pCR) with 4-6 cycles of neoadjuvant chemotherapy plus erlotinib in patients with triple negative breast cancer.

Timeline

Start: 2007-07
Primary completion: 2014-12
Completion: 2017-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	150 mg	Oral

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

Summary

Timeline

Drugs

Indications